Yanli Yang

Bengbu, 233004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

CBLB inhibits papillary thyroid cancer malignancy via negatively regulating MYCBP/c-Myc axis.

CBLB inhibits papillary thyroid cancer malignancy via negatively regulating MYCBP/c-Myc axis.

Journal: Cellular signalling

Published: December 30, 2025

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: December 23, 2025

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

Journal: Oncology reports

Published: November 19, 2025

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.

Journal: Experimental hematology & oncology

Published: May 16, 2025

TKT regulates the pentose phosphate pathway via RBKS to promote epithelial-mesenchymal transition during AML progression.

TKT regulates the pentose phosphate pathway via RBKS to promote epithelial-mesenchymal transition during AML progression.

Journal: Journal of bioenergetics and biomembranes

Published: April 10, 2025

Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.

Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.

Journal: Cell reports. Medicine

Published: April 03, 2025

MDSC subpopulation dynamics predict disease evolution: a multidimensional biomarker framework for risk assessment in MDS.

MDSC subpopulation dynamics predict disease evolution: a multidimensional biomarker framework for risk assessment in MDS.

Journal: Clinical and experimental medicine

Published: April 02, 2025

Activation of M1 macrophages promotes diabetic kidney disease by modulating glycolysis via HIF-1α-HK2 signaling pathway.

Activation of M1 macrophages promotes diabetic kidney disease by modulating glycolysis via HIF-1α-HK2 signaling pathway.

Journal: Diabetology & metabolic syndrome

Published: February 06, 2025

Analysis of the Correlation Between MDS Inflammatory Indicators and Clinical Characteristics: A Comprehensive Analysis.

Analysis of the Correlation Between MDS Inflammatory Indicators and Clinical Characteristics: A Comprehensive Analysis.

Journal: Mediators of inflammation

Published: December 16, 2024

Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.

Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.

Journal: Hematology (Amsterdam, Netherlands)

Published: April 30, 2024

Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5.

Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5.

Journal: Leukemia research

Published: October 16, 2023

RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia

RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: November 27, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026